Polyphron is a New York-based biotech company building artificial human biology for drug development. Its platform combines the Tissue Foundry, an automated system that grows donor-diverse human micro-tissue from stem cells, with the Tissue World Model, an AI simulation layer that predicts how living tissue responds to genetic, chemical, biological and environmental changes. By letting therapeutic hypotheses be tested against living human tissue, the company aims to provide the verification layer that AI-driven drug development needs before candidates reach clinical trials.
1
Round
1
Industry
4
Tags
Sep 17, 2026
Latest raise
Funding activity · 1 round
Sep 17, 2026
$20M
Seed
Led by Quiet Capital
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
